alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Home › Research › Topics › anti-amyloid-antibodies

anti-amyloid-antibodies

6 studies tagged anti-amyloid-antibodies, dated 2021-01-01 to 2026-10-09. Bibliography: BibTeX (.bib) · RIS (.ris)

Newest in this topic

  1. [Anti-amyloid antibodies against Alzheimer's disease : Lecanemab and donanemab in practice-Clinical importance, patient selection and safety management] 2026-10-09
  2. Anti-Amyloid Antibodies in the Treatment of Alzheimer's Disease: An Umbrella Review 2026-09-01
  3. Early binding of anti-amyloid antibodies to CAA drives complement activation, inflammation and ARIA in mice 2026-06-26

Studies

6 studies carry this tag.

Date range

2021 to 2026

Top journals

  • Advanced materials (Deerfield Beach, Fla.) 1
  • Der Nervenarzt 1
  • Journal of clinical medicine 1
  • Molecular neurodegeneration 1
  • The Journal of biological chemistry 1

6 journals in all.

Newest first, then by address. Each study has a usefulness score out of 100 (rubric version 4.0); tap a score to see what makes it up. Tags were assigned automatically from each study's title and summary. The same studies as a filter in the library.

  1. [Anti-amyloid antibodies against Alzheimer's disease : Lecanemab and donanemab in practice-Clinical importance, patient selection and safety management]

    ✓ Peer-reviewed alzhub usefulness score 43 out of 100. Der Nervenarzt 2026-10-09 Treatments

    Lecanemab and donanemab are the first disease-modifying therapies for early Alzheimer's disease.

  2. Anti-Amyloid Antibodies in the Treatment of Alzheimer's Disease: An Umbrella Review

    ✓ Peer-reviewed alzhub usefulness score 79 out of 100. Journal of clinical medicine 2026-09-01 Treatments

    This umbrella review included 11 systematic reviews and/or meta-analyses.

  3. Early binding of anti-amyloid antibodies to CAA drives complement activation, inflammation and ARIA in mice

    ✓ Peer-reviewed alzhub usefulness score 47 out of 100. Molecular neurodegeneration 2026-06-26 Treatments

    Anti-amyloid antibody treatment for Alzheimer's disease is linked to Amyloid-Related Imaging Abnormalities (ARIA), including vasogenic edema (ARIA-E) and microhemorrhages (ARIA-H), especially in ApoE ε4/4 carriers.

  4. Engineering anti-amyloid antibodies with transferrin receptor targeting improves brain biodistribution and mitigates ARIA

    ⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. bioRxiv 2024-07-26 Treatments

    Although the first generation of immunotherapies for Alzheimer’s disease (AD) are now clinically approved, amyloid-related imaging abnormalities (ARIA) remain a major safety problem for this class of drugs.

  5. A Therapeutic Nanovaccine that Generates Anti-Amyloid Antibodies and Amyloid-specific Regulatory T Cells for Alzheimer's Disease

    ✓ Peer-reviewed alzhub usefulness score 40 out of 100. Advanced materials (Deerfield Beach, Fla.) 2022-12-19 Treatments

    Alzheimer's disease (AD), the most common cause of dementia, is a complex condition characterized by multiple pathophysiological mechanisms including amyloid-β (Aβ) plaque accumulation and neuroinflammation in the brain.

  6. Rational affinity maturation of anti-amyloid antibodies with high conformational and sequence specificity

    ✓ Peer-reviewed alzhub usefulness score 43 out of 100. The Journal of biological chemistry 2021-01-01 Treatments

    The aggregation of amyloidogenic polypeptides is strongly linked to several neurodegenerative disorders, including Alzheimer's and Parkinson's diseases.

All topic tags with their study counts